Anthem Biosciences Limited Annual Report FY2026
Anthem Biosciences Limited Annual Report FY2026
Quality Scores
Latest Quarterly Earnings Summary
Loading latest quarter…
AI Summary
Anthem Biosciences is a premier Indian CRDMO with high-end capabilities in drug discovery, development, and manufacturing across both NCE and NBE programs. Since its 2006 incorporation, it has scaled into a large-cap business with ₹2,124 Cr in FY26 revenue and a consistent EBITDA margin profile often exceeding 35%. The business demonstrates a rare combination of scientific complexity—spanning RNAi, ADCs, and fermentation—with strong financial discipline, evidenced by its nearly debt-free status. Recent capacity expansions in fermentation and custom synthesis suggest a management geared for…
Key Changes in FY2026
Since incorporation in 2006, Anthem has evolved from a pure-play service provider into a high-end CRDMO with proprietary platforms in RNAi, ADCs, and peptides. The business has successfully climbed the value chain from basic synthesis to complex NCE and NBE programs. Between FY2020 and FY2026, revenue scaled from ₹633 Cr to ₹2,124 Cr, representing a transition from a mid-sized player to a dominant biotechnology force. Strategic investments in fermentation and custom synthesis capacity have allowed for volume-led growth. The company has diversified its revenue mix toward specialty ingredients, reducing reliance on pure R&D contracts. Recent timelines show a shift toward large-scale commercial molecules and late-phase clinical programs.
Management Commentary
Management execution is characterized by high technical competence and strategic foresight in the biotech space. The leadership has successfully scaled the business from a boutique service provider to a multi-platform CDMO with integrated capabilities in Chemistry and Biology. Communication is transparent, evidenced by regular earnings calls and detailed disclosures regarding capacity utilization and scientific staff metrics. The upgrade in credit ratings under their tenure reflects a successful derisking of the operational model. There is a clear focus on digital transformation and expanding the commercial molecule pipeline, which indicates a management team that is future-proofing the enterprise.
Financial Highlights
The business exhibits superior financial health, with revenue growing at a 3-year CAGR of 26% and profits at 21%. Operating margins are exceptional for the sector, reaching 39% in FY26, driven by specialized specialty ingredients and high-barrier Biologics services. Profitability quality is verified by consistent growth in EPS from ₹6.57 to ₹10.54 over the last three fiscal years. Capital efficiency remains a core strength, with ROCE consistently maintaining levels above 25% despite large capital expenditures. The recent upgrade to ICRA AA (Stable) further validates the strength of its balance sheet and operational cash flow generating capability.
Major Opportunities
- Exceptional ROCE profile consistently >24% during expansion
- Robust Operating Profit Margins (OPM) exceeding 35%
- Successful transition from research to commercial-scale manufacturing
Major Risks
- High customer concentration inherent to CRDMO business model
- Vulnerability to global pharmaceutical R&D spending cycles
- Significant inventory holding requirements (historically high days)
About This Annual Report
The Anthem Biosciences Limited FY2026 Annual Report is the company's flagship annual disclosure, filed with NSE / BSE. It covers the full-year business review, management discussion & analysis (MD&A), audited financial statements, director's report, corporate governance report, auditor's report, risk factors, capital allocation, subsidiaries, related-party transactions and ESG initiatives. This page consolidates the official PDF and an AI-generated summary so investors can quickly grasp what changed vs. prior years — sales growth, margin trend, cash flow quality, capex, dividends and management outlook — without having to read the entire filing.
Why Use AI?
- Summarises hundreds of pages into a focused executive briefing
- Identifies year-on-year key changes automatically
- Extracts management commentary and tone
- Highlights top risks and opportunities
- Compares business evolution vs. earlier years
- Answers your questions in plain English via Ask AI
Frequently Asked Questions
Related Research
AI Top Insights — Premium
Unlock deeper AI Top Insights, advanced comparisons, downloadable reports and premium features.